2025 Japan Anti-Migraine Drugs Market Revenue Opportunities Report
Description
The 2025 Japan Anti-Migraine Drugs Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Anti-Migraine Drugs Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in Japan's anti-migraine drugs market are Otsuka Pharmaceutical Co., Ltd., Teva Pharmaceutical Industries Ltd., Amgen Inc., and Eli Lilly and Company. Otsuka Pharmaceutical has exclusive rights in Japan to develop and commercialize Teva’s fremanezumab (AJOVY), a preventive migraine treatment with a subcutaneous injection form recently launched in an auto-injector dosage. Teva, a global leader in migraine biologics, collaborates closely with Otsuka in Japan and leads innovation in anti-CGRP monoclonal antibodies. Amgen, though primarily focused on other biopharmaceutical areas, is recognized as a key player in Japan’s larger migraine drug segment and has a strong global biopharma presence with multiple clinical programs underway, including neurological therapies. Eli Lilly is also positioned prominently by leveraging advanced migraine therapeutics globally and in Japan, contributing to market expansion through R&D and new product launches.
These companies drive the market growth through significant investments in research, strategic partnerships, and targeted therapies addressing chronic and episodic migraines. Japan’s aging population and initiatives by the Japan Headache Society further stimulate demand for innovative treatments. The market is expected to grow at a CAGR of over 8% towards 2035, with these firms leading product development, regulatory approvals, and commercialization in Japan’s migraine drug space. Their combined efforts focus on improving patient compliance, reduced side effects, and expanding access to preventive and acute migraine medications.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Anti-Migraine Drugs Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in Japan's anti-migraine drugs market are Otsuka Pharmaceutical Co., Ltd., Teva Pharmaceutical Industries Ltd., Amgen Inc., and Eli Lilly and Company. Otsuka Pharmaceutical has exclusive rights in Japan to develop and commercialize Teva’s fremanezumab (AJOVY), a preventive migraine treatment with a subcutaneous injection form recently launched in an auto-injector dosage. Teva, a global leader in migraine biologics, collaborates closely with Otsuka in Japan and leads innovation in anti-CGRP monoclonal antibodies. Amgen, though primarily focused on other biopharmaceutical areas, is recognized as a key player in Japan’s larger migraine drug segment and has a strong global biopharma presence with multiple clinical programs underway, including neurological therapies. Eli Lilly is also positioned prominently by leveraging advanced migraine therapeutics globally and in Japan, contributing to market expansion through R&D and new product launches.
These companies drive the market growth through significant investments in research, strategic partnerships, and targeted therapies addressing chronic and episodic migraines. Japan’s aging population and initiatives by the Japan Headache Society further stimulate demand for innovative treatments. The market is expected to grow at a CAGR of over 8% towards 2035, with these firms leading product development, regulatory approvals, and commercialization in Japan’s migraine drug space. Their combined efforts focus on improving patient compliance, reduced side effects, and expanding access to preventive and acute migraine medications.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
